'For
the quarter ending March 2023, standalone Net sales (including other operating income) of Pfizer has increased 4.18% to Rs 572.64 crore compared to quarter ended Mar 2022.Operating profit margin has jumped from 30.10% to 31.76%, leading to 9.92% rise in operating profit to Rs 181.87 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 13.03% to 12.22%. Purchase of finished goods cost fell from 31.79% to 26.11%. Employee cost decreased from 14.15% to 11.29%. Other expenses rose from 15.67% to 18.93%. Other income up 83.29% to Rs 31.38 crore. PBIDT rose 16.80% to Rs 213.25 crore. Provision for interest fell 34.29% to Rs 2.53 crore. Loan funds rose to Rs 41.15 crore as of 31 March 2023 from Rs 39.25 crore as of 31 March 2022. Inventories declined from Rs 448.90 crore as of 31 March 2022 to Rs 417.70 crore as of 31 March 2023.&...
Pleaselogin & subscribe to view the full report.
More Reports
|
|